Revision as of 23:50, 11 January 2020

1 regimens on this page 1 variants on this page

All lines of therapy

back to top

Study	Evidence
Hainsworth et al. 2018 (MyPathway)	Phase IIa

SMO p.W535L or other nonsynonymous mutations, or PTCH-1 loss-of-function mutations

Continued indefinitely

MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains verified protocol PubMed

@@ Line 1: / Line 1: @@
-<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''-->
-<!--Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].-->
 {| class="wikitable" style="float:right; margin-right: 5px;"
 |-
@@ Line 10: / Line 6: @@
 {{TOC limit|limit=3}}
-'''Note: this is a new type of page for HemOnc.org, as most other regimen pages are tissue-specific. We will collect published information from basket trials on these pages, as well as regimens that are FDA approved.'''
 =All lines of therapy=
 ==Vismodegib monotherapy {{#subobject:e0d17a|Regimen=1}}==
+{| class="wikitable" style="float:right; margin-left: 5px;"
+|-
+|[[#top|back to top]]
+|}
 ===Regimen {{#subobject:392a4b|Variant=1}}===
 {| class="wikitable" style="width: 50%; text-align:center;"
@@ Line 34: / Line 33: @@
 [[Category:SMO or PTCH-1 (Hedgehog) regimens]]
 [[Category:Biomarker-specific pages]]
+[[Category:Malignant solid neoplasm]]
 [[Category:Site-agnostic regimens]]